Investigating a new drug to treat liver fibrosis caused by non-alcoholic steatohepatitis
Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitis
This study is looking at a new treatment called Oxy210 that might help people with non-alcoholic steatohepatitis (NASH) by reducing liver scarring and inflammation, and it’s designed to be taken easily by mouth.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Max Biopharma, INC. NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10832060 on NIH RePORTER |
What this research studies
This research focuses on evaluating a semi-synthetic oxysterol, known as Oxy210, which may help reduce liver fibrosis associated with non-alcoholic steatohepatitis (NASH). The approach involves understanding how this compound interacts with specific molecular pathways that contribute to liver inflammation and scarring. By targeting these pathways, the research aims to develop a therapeutic option that could improve liver health in affected patients. Participants may receive the drug through oral administration, allowing for easier treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with non-alcoholic steatohepatitis and associated liver fibrosis.
Not a fit: Patients with liver fibrosis due to other causes, such as chronic alcohol use or viral hepatitis, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients suffering from liver fibrosis due to NASH, potentially improving their liver function and overall health.
How similar studies have performed: Previous research has shown promise in targeting similar molecular pathways for treating liver fibrosis, suggesting that this approach could be effective.
Where this research is happening
Los Angeles, United States
- Max Biopharma, INC. — Los Angeles, United States (Active)
Researchers
- Principal investigator: Parhami, Farhad — Max Biopharma, INC.
- Study coordinator: Parhami, Farhad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.